Background Pancreatic ductal adenocarcinoma (PDAC) is mostly refractory to immunotherapy due to immunosuppression in the tumor microenvironment and cancer cell-intrinsic T cell tolerance mechanisms. PDAC is described as a “cold” tumor type with poor infiltration by T cells and factors leading to intratumoral T cell suppression have thus received less attention. Here, we identify a… Continue reading Pancreatic cancer cell-intrinsic transglutaminase-2 promotes T cell suppression through microtubule-dependent secretion of immunosuppressive cytokines
Tag: Colorectal Cancer
New target identified for potential colorectal cancer treatment
Colorectal cancer (CRC) is a type of cancer that begins in the colon (large intestine) or rectum, which are parts of the digestive system. It typically starts as abnormal growths called polyps that form in the lining of the colon or rectum. Over time, some of these polyps can become cancerous if left untreated. CRC… Continue reading New target identified for potential colorectal cancer treatment
Scientists identify new epigenetic approach to target colorectal cancer
A little-known mouse protein disrupts cancer-causing chemical changes to genes associated with human colorectal cancer cells and potentially could be used to treat solid tumors, according to a new study.
Clinical Trials Are Testing Ways to Prevent Breast Cancer
Higher screening rates along with treatment advances have reduced breast cancer deaths by 42% in recent decades. Still, it remains the second deadliest cancer among women in the United States, with over 40,000 expected to die of the disease last year. And for the almost 4 million women living with breast cancer, the physical and mental… Continue reading Clinical Trials Are Testing Ways to Prevent Breast Cancer
Utilization of primary tumor samples for cancer neoantigen discovery
Background The use of tumor-infiltrating T lymphocytes (TIL) that recognize cancer neoantigens has led to lasting remissions in metastatic melanoma and certain cases of metastatic epithelial cancer. For the treatment of the latter, selecting cells for therapy typically involves laborious screening of TIL for recognition of autologous tumor-specific mutations, detected through next-generation sequencing of freshly… Continue reading Utilization of primary tumor samples for cancer neoantigen discovery
FAP-targeted radioligand therapy with 68Ga/177Lu-DOTA-2P(FAPI)2 enhance immunogenicity and synergize with PD-L1 inhibitors for improved antitumor efficacy
Background Fibroblast activation protein (FAP)-targeted radioligand therapy, with immunomodulatory effects, has shown efficacy in both preclinical and clinical studies. We recently reported on a novel dimeric FAP-targeting radiopharmaceutical, 68Ga/177Lu-DOTA-2P(FAPI)2, which demonstrated increased tumor uptake and prolonged retention in various cancers. However, further exploration is required to understand the therapeutic efficacy and underlying mechanisms of combining… Continue reading FAP-targeted radioligand therapy with 68Ga/177Lu-DOTA-2P(FAPI)2 enhance immunogenicity and synergize with PD-L1 inhibitors for improved antitumor efficacy
HDAC and MEK inhibition synergistically suppresses HOXC6 and enhances PD-1 blockade efficacy in BRAFV600E-mutant microsatellite stable colorectal cancer
Background B-Raf proto-oncogene, serine/threonine kinase (BRAF)V600E-mutant microsatellite stable (MSS) colorectal cancer (CRC) constitutes a distinct CRC subgroup, traditionally perceived as minimally responsive to standard therapies. Recent clinical attempts, such as BRAF inhibitors (BRAFi) monotherapy and combining BRAFi with other inhibitors, have yielded unsatisfactory efficacy. This study aims to identify a novel therapeutic strategy for this… Continue reading HDAC and MEK inhibition synergistically suppresses HOXC6 and enhances PD-1 blockade efficacy in BRAFV600E-mutant microsatellite stable colorectal cancer
Neo-adjuvant FOLFOX with and without panitumumab for patients with KRAS-wt locally advanced colon cancer: results following an extended biomarker panel on the FOxTROT Trial embedded phase II population
The FOxTROT trial has reported advantages of neoadjuvant chemotherapy (NAC) in locally advanced colon cancer (LACC). Here we present results of the embedded randomized phase II trial testing the addition of panitumumab to neoadjuvant FOLFOX compared with FOLFOX alone in RAS and BRAF-wild-type patients and with biomarker hyperselction.
Experts Forecast Cancer Research and Treatment Advances in 2025
Every new year brings excitement and anticipation for what might happen over the next 12 months. So, what’s in store for 2025 that could change the way we diagnose and treat cancer? What first-in-class therapeutics could offer new life-saving options to patients? What scientific discovery will have everyone talking? In 2024, we saw the approval… Continue reading Experts Forecast Cancer Research and Treatment Advances in 2025